Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

TARGINIQ

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

Standard Dose
5MG;10MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview TARGINIQ is listed in Drugs@FDA under application 205777 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 5MG;10MG Sponsor PURDUE PHARMA LP Submission history Latest submission status date: 2018-09-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview TARGINIQ is listed in Drugs@FDA under application 205777 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 5MG;10MG Sponsor PURDUE PHARMA LP Submission history Latest submission status date: 2018-09-18 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.